Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...

This is the goal which Neurizon Therapeutics Ltd – the company formerly known as PharmAust – is pursuing through development ...

Spark Plus, an Asia-Pacific corporate advisory firm, puts a target price of 69.6 cents on Neurizon – a 225% upside to its ...

OMPD will offer Neurizon a range of attractive incentives for NUZ-001. These include reduced regulatory fees, free protocol assistance, and, importantly, 10 years of market exclusivity in the ...

Neurizon partners with GenieUs for the Phase 1 trial, using genomic profiling to enhance patient stratification and deepen therapeutic insights. SYDNEY, AUSTRALIA, November 7, 2024 /EINPresswire ...

Clinical-stage biotech Neurizon Therapeutics – formerly PharmAust – made significant strides advancing its treatments for neurodegenerative diseases during the September 2024 quarter.

While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...

MELBOURNE, Australia, Oct. 15, 2024 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing treatments for ...

Spark Plus, an Asia-Pacific corporate advisory firm, puts a target price of 69.6 cents on Neurizon – a 225% upside to its October 23 price. In a research note Spark Plus said Neurizon ...

The September 2024 quarter saw Neurizon Therapeutics receive positive interim results from the use of NUZ-001 to treat Amyotrophic Lateral Sclerosis. During this period, it advanced clinical-stage ...